Canaccord cuts Intercept to hold, calls Alfasigma deal “best possible outcome” (ICPT)

Maksim Labkouski

Intercept Pharmaceuticals (NASDAQ:ICPT) has been downgraded to hold by Canaccord Genuity in the wake of news that the biotech group has agreed to be acquired by Alfasigma for $19 per share in cash.

Canaccord said in a note that it

Leave a Comment